Collaborative Medicinal Development Enrolls First Patient In a Randomized, Placebo-Controlled Clinical Trial of CuATSM For The Treatment of Amyotrophic Lateral Sclerosis

MILL VALLEY, Calif. and MELBOURNE, Australia, Oct. 14, 2019 /PRNewswire/ — Collaborative Medicinal Development, LLC) (“CMD”), a clinical stage biopharmaceutical company with a portfolio of candidates for treatment of neurological and neuropsychiatric...
SEARCH FOR STUDIES